Novartis AG said profit will rise this year as new medicines help offset the competition it expects from copycats of its best-selling medicine.
Core operating profit will likely grow by a high single- to a low double-digit percentage, the Swiss drugmaker said Friday. Sales will probably increase at a mid- to high-single digit pace.
Novartis is facing a raft of patent expiries for some of its biggest drugs, with top-selling heart medicine Entresto expected to face generic competitors in the US mid-year. The drugmaker has said its newer therapies will continue to drive growth.
The patent expiries are a test of Chief Executive Officer Vas Narasimhan’s years-long overhaul of the company, with its focus narrowed to specific types of diseases. Last year Narasimhan issued what many investors saw as a cautious forecast at the beginning of the year, then repeatedly raised it in successive quarters.
Novartis shares have risen about 1% in the past 12 months, less than those of cross-town rival Roche Holding AG. Roche on Thursday said profit excluding some items would probably grow in the high single-digit range at constant currencies this year, outpacing revenue.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.